Rare diseases
Investigational molecules
Locations
Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration
CzechiaA Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration
AustriaRandomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration
EstoniaA study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema
BulgariaStudy of two initial doses of aflibercept for patients with newly diagnosed neovascular age-related macular degeneration
AustriaStudy on Regorafenib for Patients with Advanced RAS-Mutant Colorectal Cancer Using Regorafenib and Drug Combination
ItalyStudy on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease
AustriaStudy on Vitrectomy, Alteplase, and Aflibercept for Patients with Wet Age-Related Macular Degeneration and Submacular Hemorrhage
GermanySafety and Efficacy of Two Doses of OCUL101 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration
CzechiaA Phase 2 Study of Aganirsen Eye Drops to Extend Intravitreal Aflibercept Injection Interval in Patients with Wet Age‑Related Macular Degeneration
FranceA study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema
GermanyA study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema
CzechiaTell us about your condition – we search every trial in Europe and connect you with the right site.
